Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-01

Study Completion Date

2022-10-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the safety associated with the addition of sulfasalazine to stereotactic radiosurgery for recurrent glioblastoma. Sulfasalazine is a potential tumor selective radiosensitizer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sorafenib in Newly Diagnosed High Grade Glioma

NCT00884416

Glioblastoma Gliosarcoma Anaplastic Astrocytoma +2 more

COMPLETED PHASE1

SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy

NCT00004868

Brain and Central Nervous System Tumors

COMPLETED PHASE1/PHASE2

Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00165477

Glioblastoma Gliosarcoma Malignant Gliomas

COMPLETED PHASE2

Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

NCT00093613

Adult Anaplastic Astrocytoma Adult Anaplastic Oligodendroglioma Adult Giant Cell Glioblastoma +2 more

COMPLETED PHASE1

Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma

NCT01250470

Anaplastic Astrocytoma Anaplastic Oligoastrocytoma Anaplastic Oligodendroglioma +5 more

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Glioblastoma is the most aggressive and most common type of primary brain cancer. Standard treatment at diagnosis is surgery followed by high dose radiation therapy and chemotherapy. Despite initial treatment nearly all patients will experience recurrence of the tumor with a dismal prognosis. There is no consensus on standard of care at recurrence. Reoperation is associated with a high risk of complications and further conventional radiation therapy is often not possible as the maximum tolerated dose to the normal brain has already been given. In addition most tumors have developed resistance towards chemotherapy. Stereotactic radiosurgery (SRS) may be administered despite prior initial radiation treatment but in order to avoid radiation induced complications only limited doses to limited tumor volumes can be applied.

Developing new strategies to improve the effect of radiation selectively on tumor cells without simultaneously increase the radiation induced damage of normal brain would be valuable.

The investigators have shown in experimental studies that the drug sulfasalazine enhances the number of cancer cells that dies as result of radiation therapy and thereby improves survival in combination with SRS in animals with glioblastoma. Sulfasalazine inhibits the production of an antioxidant that normally protects the tumor against radiation. Hopefully the trial will result in a new and more effective treatment option for patients with recurrent glioblastoma.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioma Glioblastoma Recurrent Glioblastoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

3 + 3 dose escalation design: Cohort 1 (3-6 patients): 1.5 gr Sulfasalazine x 1 for 3 days Cohort 2 (3-6 patients): 3.0 gr Sulfasalazine x 1 for 3 days Cohort 3 (3-6 patients): 4.5 gr SSulfasalazine x 1 for 3 days Cohort 4 (3-6 patients): 6.0 gr Sulfasalazine x 1 for 3 days

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sulfasalazine in addition to stereotactic radiosurgery

3 + 3 dose escalation The first cohort of 3-6 patients will receive 1.5 g Sulfasalazine daily for 3 days before single fraction stereotactic radiosurgery utilizing 12 Gy prescription dose to the tumor margin.

The second, third and fourth cohort will receive 3 days pretreatment with 3 g, 4.5 g and 6 g Sulfasalazine, respectively, before 12 Gy single fraction stereotactic radiosurgery.

Group Type OTHER

Sulfasalazine

Intervention Type DRUG

Sulfasalazine combined with stereotactic radiosurgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sulfasalazine

Sulfasalazine combined with stereotactic radiosurgery

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Stereotactic radiosurgery

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically verified glioblastoma multiforme with recurrence (first or second relapse, all subtypes) based on the Response Assessment in Neuro-Oncology criteria.
* Prior standard therapy for newly diagnosed glioblastoma consisting of surgery, standard fractionated radiotherapy to 60 Gy concomitant with Temozolomide
* Has been informed of other treatment options
* Must be eligible to gamma knife treatment
* Tumor size ≤ 3 cm in diameter (≤ 15 cm3 ) on MRI dated no more than 30 days before SRS treatment
* Must be at least 18 years of age
* Must be ambulatory with a Karnofsky performance status of ≥ 70
* Life expectancy \> 12 weeks
* Laboratory parameters for vital functions should be in the normal reference range. Laboratory abnormalities that are not clinically significant are generally permitted, except for the following laboratory parameters, which must be within the ranges specified:

Hematology: White blood cell count: ≥ 3.0 x 109/l, Platelet count:: ≥ 100 x 109/l, Hemoglobin: ≥ 100 g/l, Total bilirubin level: \<1.5 times the upper limit of normal (ULN) (except in patients with Gilbert's Syndrome who must have a total bilirubin less than 51,3 µmol/L), alanine aminotransferase \< 3 times the ULN, Creatinine \< 1.5 times the ULN, Normal prothrombin time / international normalized ratio (PT INR) \< 1.4, Absolute neutrophil count: ≥ 1 x109/L without the support of filgrastim.

* More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients' toxicities must have recovered to a grade 1 or less. Patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less or as specified in the eligibility criteria.
* Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to national/local regulations

Exclusion Criteria

* Allergy to sulfa drugs
* Adverse reactions to salicylates
* Known hypersensitivity to sulfasalazine, its metabolites or any of the excipients (Povidone; Maize starch; magnesium stearate; colloidal silicon dioxide)
* Eligible to alternative standard treatments with temozolomide
* Treatment with sulfasalazine after glioblastoma diagnosis
* Participation in pharmacokinetic trial within 4 weeks
* Participation in immunotherapy trial within 4 weeks
* History of psychological symptoms affecting ability to consent to and/or fulfill the protocol
* Other malignant diseases and multiple sclerosis
* Pregnant or breast feeding patients.
* Porphyria
* Kidney of liver deficiencies
* Glucose-6-phosphate dehydrogenase deficiency
* Severe allergy or bronchial asthma
* History of erythema multiforme
* Significant heart failure or renal failure
* Intestinal or urinary obstruction
* Any reason why, in the opinion of the investigator, the patient should not participate (e.g. not able to comply with study procedures).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No